Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$37.35
-0.75-1.97%
At close: -
$37.35
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Revolution Medicines Analyst Ratings and Price Targets | NASDAQ:RVMD | Benzinga
Revolution Medicines Inc has a consensus price target of $60 based on the ratings of 19 analysts. The high is $87 issued by Guggenheim on December 3, 2024. The low is $23 issued by Goldman Sachs on March 1, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Stifel, and Needham on March 3, 2025, February 27, 2025, and February 27, 2025, respectively. With an average price target of $70 between HC Wainwright & Co., Stifel, and Needham, there's an implied 87.42% upside for Revolution Medicines Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Stifel
Needham
UBS
Wedbush
1calculated from analyst ratings
Analyst Ratings for Revolution Medicines
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/03/2025 | Buy Now | 95.45% | HC Wainwright & Co. | Robert Burns42% | $72 → $73 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 108.84% | Stifel | Benjamin Burnett46% | $80 → $78 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 57.97% | Needham | Ami Fadia61% | $60 → $59 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 90.09% | UBS | Eliana Merle46% | $65 → $71 | Maintains | Buy | Get Alert |
| 12/06/2024 | Buy Now | 79.38% | Wedbush | Robert Driscoll44% | $70 → $67 | Maintains | Outperform | Get Alert |
| 12/06/2024 | Buy Now | 66% | Needham | Ami Fadia61% | $68 → $62 | Maintains | Buy | Get Alert |
| 12/04/2024 | Buy Now | 92.77% | HC Wainwright & Co. | Robert Burns42% | $64 → $72 | Maintains | Buy | Get Alert |
| 12/03/2024 | Buy Now | 132.93% | Guggenheim | Michael Schmidt54% | $82 → $87 | Maintains | Buy | Get Alert |
| 12/03/2024 | Buy Now | 82.06% | Needham | Ami Fadia61% | $68 → $68 | Reiterates | Buy → Buy | Get Alert |
| 12/03/2024 | Buy Now | 90.09% | JP Morgan | Eric Joseph46% | $63 → $71 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 87.42% | Wedbush | Robert Driscoll44% | $59 → $70 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 82.06% | Needham | Ami Fadia61% | $61 → $68 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 71.35% | HC Wainwright & Co. | Robert Burns42% | $62 → $64 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 68.67% | JP Morgan | Eric Joseph46% | $54 → $63 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 87.42% | Piper Sandler | Joseph Catanzaro41% | $57 → $70 | Maintains | Overweight | Get Alert |
| 10/28/2024 | Buy Now | 119.54% | Guggenheim | Michael Schmitz42% | $72 → $82 | Maintains | Buy | Get Alert |
| 10/28/2024 | Buy Now | 60.64% | Oppenheimer | Jay Olson62% | $55 → $60 | Maintains | Outperform | Get Alert |
| 10/28/2024 | Buy Now | 63.32% | Needham | Ami Fadia61% | $61 → $61 | Reiterates | Buy → Buy | Get Alert |
| 10/25/2024 | Buy Now | 63.32% | Needham | Ami Fadia61% | $61 → $61 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 63.32% | Needham | Ami Fadia61% | $61 → $61 | Reiterates | Buy → Buy | Get Alert |
| 10/07/2024 | Buy Now | 63.32% | Needham | Ami Fadia61% | $61 → $61 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2024 | Buy Now | 60.64% | Barclays | Peter Lawson41% | $54 → $60 | Maintains | Overweight | Get Alert |
| 08/12/2024 | Buy Now | 49.93% | HC Wainwright & Co. | Robert Burns42% | $56 → $56 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 44.58% | JP Morgan | Eric Joseph46% | $55 → $54 | Maintains | Overweight | Get Alert |
| 08/08/2024 | Buy Now | 57.97% | Wedbush | Robert Driscoll44% | $59 → $59 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2024 | Buy Now | 63.32% | Needham | Ami Fadia61% | $62 → $61 | Maintains | Buy | Get Alert |
| 07/18/2024 | Buy Now | 44.58% | Barclays | Peter Lawson41% | $52 → $54 | Maintains | Overweight | Get Alert |
| 07/16/2024 | Buy Now | 47.26% | Oppenheimer | Jay Olson62% | $45 → $55 | Maintains | Outperform | Get Alert |
| 07/16/2024 | Buy Now | 47.26% | B of A Securities | Alec Stranahan33% | $48 → $55 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | 49.93% | HC Wainwright & Co. | Robert Burns42% | $44 → $56 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | 66% | Needham | Ami Fadia61% | $46 → $62 | Maintains | Buy | Get Alert |
| 07/12/2024 | Buy Now | 39.22% | Barclays | Peter Lawson41% | → $52 | Initiates | → Overweight | Get Alert |
| 07/08/2024 | Buy Now | 68.67% | Jefferies | — | → $63 | Initiates | → Buy | Get Alert |
| 05/13/2024 | Buy Now | 17.8% | HC Wainwright & Co. | Robert Burns42% | $44 → $44 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 23.16% | Needham | Ami Fadia61% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 23.16% | Wedbush | Robert Driscoll44% | $42 → $46 | Maintains | Outperform | Get Alert |
| 04/12/2024 | Buy Now | 20.48% | Oppenheimer | Jay Olson62% | $43 → $45 | Maintains | Outperform | Get Alert |
| 04/12/2024 | Buy Now | 23.16% | Needham | Ami Fadia61% | $36 → $46 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 28.51% | Raymond James | Laura Prendergast28% | $36 → $48 | Upgrade | Outperform → Strong Buy | Get Alert |
| 04/08/2024 | Buy Now | -3.61% | Needham | Ami Fadia61% | $36 → $36 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 15.13% | Piper Sandler | Joseph Catanzaro41% | → $43 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 17.8% | HC Wainwright & Co. | Robert Burns42% | $28 → $44 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 90.09% | Morgan Stanley | — | $84 → $71 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | 12.45% | Wedbush | David Driscoll53% | $41 → $42 | Maintains | Outperform | Get Alert |
| 01/16/2024 | Buy Now | -3.61% | Raymond James | Laura Prendergast28% | $30 → $36 | Maintains | Outperform | Get Alert |
| 01/05/2024 | Buy Now | -8.97% | B of A Securities | Alec Stranahan33% | → $34 | Upgrade | Neutral → Buy | Get Alert |
| 12/20/2023 | Buy Now | 7.1% | UBS | Eliana Merle46% | → $40 | Initiates | → Buy | Get Alert |
| 11/16/2023 | Buy Now | -19.68% | Raymond James | Dane Leone45% | → $30 | Initiates | → Outperform | Get Alert |
| 11/13/2023 | Buy Now | -25.03% | HC Wainwright & Co. | Robert Burns42% | $32 → $28 | Maintains | Buy | Get Alert |
| 11/07/2023 | Buy Now | 4.42% | JP Morgan | Eric Joseph46% | $47 → $39 | Maintains | Overweight | Get Alert |
| 11/07/2023 | Buy Now | -3.61% | Needham | Ami Fadia61% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 10/26/2023 | Buy Now | -14.32% | HC Wainwright & Co. | Robert Burns42% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 10/23/2023 | Buy Now | 15.13% | Oppenheimer | Jay Olson62% | $40 → $43 | Maintains | Outperform | Get Alert |
| 10/23/2023 | Buy Now | -3.61% | Needham | Ami Fadia61% | $34 → $36 | Maintains | Buy | Get Alert |
| 10/12/2023 | Buy Now | -8.97% | Needham | Ami Fadia61% | → $34 | Reiterates | Buy → Buy | Get Alert |
| 09/21/2023 | Buy Now | 25.84% | Stifel | Benjamin Burnett46% | $37 → $47 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | -8.97% | Needham | Ami Fadia61% | $35 → $34 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 7.1% | Oppenheimer | Jay Olson62% | $35 → $40 | Maintains | Outperform | Get Alert |
| 08/02/2023 | Buy Now | -14.32% | HC Wainwright & Co. | Robert Burns42% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | -6.29% | Needham | Ami Fadia61% | $31 → $35 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -6.29% | Oppenheimer | Jay Olson62% | → $35 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | -14.32% | Needham | Ami Fadia61% | $34 → $32 | Maintains | Buy | Get Alert |
| 04/12/2023 | Buy Now | -14.32% | HC Wainwright & Co. | Robert Burns42% | → $32 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | -38.42% | Goldman Sachs | Chris Shibutani56% | $20 → $23 | Maintains | Neutral | Get Alert |
| 02/28/2023 | Buy Now | 1.74% | Guggenheim | Michael Schmitz42% | → $38 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -6.29% | Oppenheimer | Jay Olson62% | $30 → $35 | Maintains | Outperform | Get Alert |
| 02/28/2023 | Buy Now | 1.74% | Needham | Ami Fadia61% | $32 → $38 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | 1.74% | JP Morgan | Eric Joseph46% | $32 → $38 | Upgrade | Neutral → Overweight | Get Alert |
| 12/14/2022 | Buy Now | -17% | Needham | Ami Fadia61% | → $31 | Initiates | → Buy | Get Alert |
| 12/08/2022 | Buy Now | -14.32% | HC Wainwright & Co. | Robert Burns42% | $30 → $32 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | -19.68% | HC Wainwright & Co. | Robert Burns42% | $37 → $30 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | -19.68% | Oppenheimer | Jay Olson62% | → $30 | Initiates | → Outperform | Get Alert |
| 08/17/2022 | Buy Now | -0.94% | HC Wainwright & Co. | Robert Burns42% | $40 → $37 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | -19.68% | SVB Leerink | Jonathan Chang38% | $31 → $30 | Maintains | Outperform | Get Alert |
| 05/20/2022 | Buy Now | -35.74% | B of A Securities | Alec Stranahan33% | → $24 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Revolution Medicines (RVMD) stock?
The latest price target for Revolution Medicines (NASDAQ:RVMD) was reported by HC Wainwright & Co. on March 3, 2025. The analyst firm set a price target for $73.00 expecting RVMD to rise to within 12 months (a possible 95.45% upside). 40 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Revolution Medicines (RVMD)?
The latest analyst rating for Revolution Medicines (NASDAQ:RVMD) was provided by HC Wainwright & Co., and Revolution Medicines maintained their buy rating.
When was the last upgrade for Revolution Medicines (RVMD)?
The last upgrade for Revolution Medicines Inc happened on April 10, 2024 when Raymond James raised their price target to $48. Raymond James previously had an outperform for Revolution Medicines Inc.
When was the last downgrade for Revolution Medicines (RVMD)?
There is no last downgrade for Revolution Medicines.
When is the next analyst rating going to be posted or updated for Revolution Medicines (RVMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revolution Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revolution Medicines was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.
Is the Analyst Rating Revolution Medicines (RVMD) correct?
While ratings are subjective and will change, the latest Revolution Medicines (RVMD) rating was a maintained with a price target of $72.00 to $73.00. The current price Revolution Medicines (RVMD) is trading at is $37.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.